EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes

Christian Klemann iD, Olga Kordonouri iD

Diabetes Care · 01.10.2026 · 49 (10) · 1790-1794

DOI: 10.2337/dc26-0543 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Diabetes Care, online erschienen am 28.07.2026. Verfasst von Christian Klemann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department for Pediatric Immunology, Rheumatology & Infectiology, Hospital for Children and Adolescents, Leipzig University, Leipzig, Germany. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Herpesvirus 4, Human, Antibodies, Monoclonal, Humanized, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Teplizumab delays progression from stage 2 to stage 3 type 1 diabetes (T1D). Epstein-Barr virus (EBV) reactivation after teplizumab is usually transient and mild. We report EBV reactivation-associated secondary hemophagocytic lymphohistiocytosis (HLH) in an adult with trisomy 21 who was treated with teplizumab. RESEARCH DESIGN AND METHODS We describe the clinical course, virologic testing, histopathology, treatment, and follow-up of a 44-year-old man with trisomy 21 and stage 2 T1D after a 14-day teplizumab course. RESULTS Six days after completion of the 14-day teplizumab course, he developed respiratory, hepatic, and renal failure. EBV PCR peaked at >2,000,000 copies/mL; serology confirmed reactivation. Lymph node biopsy showed EBV-associated lymphoproliferation, and criteria for secondary HLH were fulfilled (HScore 238). Dexamethasone and four weekly rituximab doses were associated with clinical, biochemical, and virologic recovery. At 12 months, he remained clinically stable with stage 2 T1D and no insulin treatment. CONCLUSIONS This case documents EBV reactivation-associated secondary HLH after teplizumab treatment in a patient with trisomy 21. Causality cannot be established, and the absence of pretreatment EBV PCR limits assessment of whether preexisting EBV DNAemia at treatment initiation contributed to the poor outcome. The observation raises a plausible but unproven host-virus-drug interaction and supports early EBV PCR and HLH evaluation after severe inflammatory deterioration after teplizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticHerpesvirus 4, HumanAntibodies, Monoclonal, HumanizedDiabetes Mellitus, Type 1Down SyndromeEpstein-Barr Virus InfectionsHumansMaleAdultVirus Activation

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department for Pediatric Immunology, Rheumatology & Infectiology, Hospital for Children and Adolescents, Leipzig University, Leipzig, Germany.
  • Auf der Bult Children's Hospital, Hannover, Germany.

ORCID-Profile: Christian Klemann, Olga Kordonouri

Zitieren

APA

Klemann, C., & Kordonouri, O. (2026). Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes. Diabetes Care, 49(10), 1790-1794. https://doi.org/10.2337/dc26-0543

Vancouver

Klemann C, Kordonouri O. Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes. Diabetes Care. 2026;49(10):1790-1794. doi:10.2337/dc26-0543

BibTeX
@article{Klemann2026,
  author = {Klemann, Christian and Kordonouri, Olga},
  title = {Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes},
  journal = {Diabetes Care},
  year = {2026},
  volume = {49},
  number = {10},
  pages = {1790--1794},
  doi = {10.2337/dc26-0543}
}
Kostenlos starten →